Company intelligence / Profile preview

AtoGen

Daejeon, South Koreaatogen.kr ↗

Ownership: Private
Development stage: Preclinical

Overview

AtoGen has developed probiotic strains such as L.plantarum HAC01 showing anti-diabetic and anti-obesity effects, and L.plantarum ATG-K2 with anti-vaginitis and anti-obesity properties. They focus on modulating the human microbiota to treat diseases or improve health.

Therapeutic areas: GastroenterologyEndocrinologyWomen's Health
Modalities: Microbiome therapeuticsFunctional health food ingredientsProbiotics
Industry: Biotech

Drug pipeline

5 assets

HAC01

Pre-clinical

Indications: Not specified

4 more assets in the full pipeline.

Request access →

Partnerships

No specific major pharma or biotech partnerships disclosed publicly; however, they have received investments from SBI Investment among others.

Beyond the preview

Go deeper on AtoGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtoGen.

Explore the full profile